Loading clinical trials...
Loading clinical trials...
An Investigator-initiated, International, Multi-centre, Prospective, Randomized, Open-label, Parallel-group, Superiority, and Pragmatic Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis.
Conditions
Interventions
Liberal phosphate target
Intensive phosphate target
Locations
115
Australia
Royal Prince Alfred Hosptial
Camperdown, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Western Sydney Renal Service
Westmead, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Start Date
December 10, 2019
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2028
Last Updated
July 1, 2025
NCT04128189
NCT06933472
NCT05283512
NCT06314503
NCT01802034
NCT06438445
Lead Sponsor
The University of Queensland
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions